

# Rolapitant license



LEERINK SWANN

- Exclusive worldwide license obtained from OPKO Health, Inc. in December 2010
  - OPKO had acquired certain NK-1 receptor related assets in 2010, including rolapitant from Schering-Plough Corporation (SGP), as part of a U.S. FTC requirement to divest certain assets in connection with the SGP combination with Merck.
  - Paid \$6M upfront and issued 1.5M shares of Series O preferred stock.
  - Up to \$30M in payments for regulatory and initial commercial sales milestones
  - Up to an aggregate of \$85M if specified levels of annual net sales are achieved
  - Will pay OPKO tiered royalties on the amount of annual net sales in the U.S. and EU at percentage rates from the low teens to low twenties, which Tesaro believes will result in an effective royalty rate in the low teens